Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic

Detalles Bibliográficos
Autores principales: McGoran, John, Wilson, Alan, McErlain, Shannan, Kennedy, Noreen, Masterson, Caroline, Collins, Caroline, Morrison, Graham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666859/
https://www.ncbi.nlm.nih.gov/pubmed/34966537
http://dx.doi.org/10.1136/flgastro-2020-101760

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666859/
https://www.ncbi.nlm.nih.gov/pubmed/34966537
http://dx.doi.org/10.1136/flgastro-2020-101760

Ejemplares similares